Table 3.
Disease-free survival, progression-free survival, and overall survival of each metastatic triple-negative breast cancer group.
| Group | Recurrence of mTNBC after Curative Surgery |
|||
|---|---|---|---|---|
| De Novo mTNBC | Nonrefractory mTNBC | Refractory mTNBC | ||
| Median, Months | Refractory mTNBC after Surgery |
Nonresectable TNBC d/t Progression during NAC |
||
| DFS (range) | - | 30.1 (18.3–217.9) |
7.6 (7.4–17.9) |
|
| PFS (95% CI) | 3.8 (3.3–4.3) |
6.2 (5.2–7.2) |
4.5 (3.7–5.3) |
3.7 (1.6–5.8) |
| 4.2 (1.6–5.8) | ||||
| 2nd PFS (range) | 3.7 | 5.3 | 3.0 | 2.1 |
| 2.6 (0–25.0) | ||||
| OS (95% CI) | 17.3 (15.9–18.7) |
24.8 (21.4–28.2) |
14.4 (12.5–16.5) |
12.9 (9.7–16.1) |
| 14.3 (12.5–16.1) | ||||
Abbreviations: mTNBC, metastatic triple-negative breast cancer; NAC, neoadjuvant chemotherapy; DFS, disease-free survival; PFS, progression-free survival; OS, overall survival; 2nd PFS, progression-free survival from second-line palliative chemotherapy to disease progression or death.